Mark Cuban's Cost Plus Drug Com­pa­ny adds new SGLT2 in­hibitor Bren­zavvy for type 2 di­a­betes

Mark Cuban’s Cost Plus Drug Com­pa­ny is bring­ing an­oth­er brand-name type 2 di­a­betes treat­ment un­der its wing.

Ther­a­cos­Bio’s re­cent­ly ap­proved SGLT2 in­hibitor Bren­zavvy is now avail­able by pre­scrip­tion through Cuban’s Cost Plus Drugs at $47.85 for a 30-day sup­ply, the drug­mak­er an­nounced Thurs­day.

“We’ve al­ways want­ed to be able to bring this for­ward on an af­ford­able ba­sis to the type 2 di­a­bet­ic pa­tient pop­u­la­tion,” Ther­a­cos­Bio CEO Al­bert Collinson told End­points News. “The sim­ple fact is most peo­ple don’t get ac­cess to new med­ica­tions be­cause their health in­sur­ance makes it dif­fi­cult or it’s as­so­ci­at­ed with sig­nif­i­cant ex­pense.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER